Exclusive Financial Advisor to Nurami Medical Ltd.
- February 20, 2025
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor to Nurami Medical Ltd. on its $30 million financing
Nurami Medical Ltd. (“Nurami”), a privately-held medical technology company that develops soft tissue regeneration technologies, has completed a capital funding round that is expected to result in $30 million in financing for the company. The proceeds from the financing will be used for i) the commercialization of their 510(k) cleared biomimetic scaffold product, ArtiFascia, that enhances tissue ingrowth to address cerebrospinal fluid leaks, and ii) the clinical development of ArtiFix, a 3-in-1 sealant patch with a scaffold layer for use in cranial and spinal repair.
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Investment Banking
Eric Tansky
Title:Managing Director, Head of Medical Technology Investment Banking
Jonathan Lasker
Title:Managing Director, Mergers & Acquisitions Investment Banking
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2025 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 7646269.1